

PBH **ADHD** Clinical Practice Guideline Measurements Information to Providers

PBH has adopted Clinical Practice Guidelines for many psychiatric and developmental disorders. These are meant to be used by providers, PBH Utilization Management, and consumers to guide good care. These are guidelines and do not preclude good clinical judgment. The Guidelines can be found on the PBH website at <http://www.pbhcare.org/guidelinearticles.asp>. If you would like a hard copy of these guidelines please contact Jane Creed at 704-743-2100

On an annual basis, in July, PBH will use two (2) of these guidelines and measure at least two (2) important data points in each guideline. The purpose of this communiqué is to inform providers of the **ADHD** guideline measurements.

The American Academy of Child and Adolescent Psychiatry ADHD guidelines recommend that the mainstay of treatment for ADHD is medication. The guidelines also stress the importance of continued treatment with medication and periodic follow up to evaluate the effectiveness of treatment.

Measurement # 1

PBH will measure the percent of children between age 6 and 18 with the diagnosis of ADHD who are seen by a prescriber within 30 days of being placed on a drug that treats ADHD. There must be a 4 month gap in treatment with an ADHD drug to enter the cohort. This will measure continuity and follow up.

Measurement # 2


This measurement will calculate the percent of children in the above cohort who remain on medication for 210 days and see a provider at least 2 times during that period in addition to the first follow up visit. This will measure adherence to medication and continuity of care.

These reviews will be done on an annual basis and the results will be shared with PBH providers. PBH will work with the PBH Clinical Advisory Committee to evaluate if there is adherence to these guidelines and to recommend any measure needed to increase compliance.

To view all initiatives go to the PBH Clinical Practice Guideline page under “Practice Guideline Initiatives.”

<http://www.pbhcare.org/guidelinearticles.asp>

We appreciate your cooperation in these initiatives. PBH believes this will enhance the care of our patients.

A handwritten signature in black ink, appearing to read "C. B. Hummel, MD". The signature is fluid and cursive, with a large initial "C" and "H".

Craig B. Hummel, MD
PBH Medical Director

4/23/2009